Accessibility Menu
PainChek logo

PainChek(ASX) PCK

Market CapA$22.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-81%
5 Year-77%
1 Year-74%
1 Month+10%
A$0.12
+4.55%
+0.00Today
PainChek last closing stock price
MetricPriceDate
Last closeAUD 0.122026-09-08
PainChek stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+17.35%AUD 0.102026-09-01
1 month+9.52%AUD 0.112026-08-07
3 month-14.81%AUD 0.142026-06-10
Year to date-60.34%AUD 0.292025-12-31
1 year-73.86%AUD 0.442025-09-08
3 year-58.93%AUD 0.282023-09-08
5 year-77.45%AUD 0.512021-09-09
Since inception-81.01%AUD 0.582018-01-22

PainChek Financials at a Glance

Market Cap

A$22.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$6.25M

Net Income (TTM)

-A$14.35M

EPS (TTM)

-A$0.04

P/E Ratio

-2.53

Dividend

A$0.00

Beta (Volatility)

0.00 (Low)

Price

A$0.12

Volume

100,684

Open

A$0.11

Previous Close

A$0.12

Daily Range

A$0.11 - A$0.12

52-Week Range

A$0.09 - A$1.05

Estimated Earnings Date

Mar 3, 2027

PCK News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PainChek

PainChek Limited is a healthcare technology company focused on developing mobile applications for pain assessment. The company's flagship product, PainChek, utilizes advanced facial recognition software to analyze video recordings, enabling accurate pain detection, particularly for patients with dementia.

Products and Services
  • PainChek app for real-time pain assessment
  • Facial recognition technology for accurate pain detection
  • Mobile platform designed for healthcare professionals
Growth Outlook
  • Recent revenue growth of 103% year-over-year in Q2 2025
  • Expansion into new markets expected to drive future sales
  • Increased demand for digital health solutions in aging populations
Financial Highlights
  • Q2 2025 revenue of AUD 1.73 million, up from AUD 0.85 million in Q4 2024
  • Gross profit margin improved to 28.8% in Q2 2025
  • Cash reserves increased to AUD 4.78 million in Q2 2025
PainChek Limited operates in the healthcare information services sector, providing innovative solutions to address pain management challenges. The company's technology is particularly relevant in the context of an aging population, where effective pain assessment is crucial. The recent financial performance indicates a positive trajectory, with significant revenue growth and improved gross profit margins. The increase in cash reserves also positions the company well for future investments and operational needs. As the demand for digital health solutions continues to rise, PainChek is strategically positioned to capitalize on these trends, making it an intriguing option for potential investors.
AI Generated • Aug 27, 2026

Industry

Health Care Technology

CEO

Philip Daffas, MBA

Headquarters

Sydney, NSW 2000, AU

PCK Financials

Key Financial Metrics (TTM)

Gross Margin

70.53%

Operating Margin

-264.97%

Net Income Margin

-238.78%

Return on Equity

-1688.04%

Return on Capital

-351.75%

Return on Assets

-117.14%

Earnings Yield

-39.53%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$22.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

209.01M

Volume

100.68K

Avg. Volume

149.55K

Financials (TTM)

Gross Profit

A$3.40M

Operating Income

-A$16.74M

EBITDA

-A$15.40M

Operating Cash Flow

-A$14.94M

Capital Expenditure

-A$23.29K

Free Cash Flow

-A$14.96M

Cash & ST Invst.

A$5.99M

Total Debt

A$4.25M

PainChek Performance Analysis

PainChek annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 1,949,51399.2%
20242024-06-30AUD 2,665,18836.7%
20252025-06-30AUD 3,357,66726.0%
20262026-06-30AUD 3,742,07111.4%
PainChek sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3121.2%
Q42025-06-30-48.6%
Q22025-12-31103.5%
Q42026-06-3015.8%
PainChek annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.0615.8%
20242024-06-30AUD -0.06-2.9%
20252025-06-30AUD -0.04-21.2%
20262026-06-30AUD -0.04-1.8%
PainChek sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3140.6%
Q42025-06-3036.8%
Q22025-12-31-92.5%
Q42026-06-3012.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$2.01M

+46.8%

Gross Profit

A$2.14M

+554.8%

Gross Margin

1.07%

N/A

Market Cap

A$22.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$919.63K

N/A

Employees

25

N/A

Net Income

-A$4.23M

+15.5%

EBITDA

-A$5.31M

-6.5%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$5.99M

+68.3%

Total Debt

A$4.25M

N/A

Accounts Receivable

A$1.53M

+193.4%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$4.25M

N/A

Return on Assets

-1.17%

N/A

Return on Invested Capital

234.71%

N/A

Free Cash Flow

-A$4.28M

-35.4%

Operating Cash Flow

-A$4.28M

-36.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MX1.AXMicro-X Limited
A$0.02-4.76%
IMU.AXImugene Limited
A$0.07-4.41%
BMT.AXBeamtree Holdings Limited
A$0.11-4.35%
IPD.AXImpediMed Limited
A$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$46.34-0.10%
NOKNokia
$10.03+0.03%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$117.28+0.10%
INTCIntel
$95.80+0.05%

Questions About PCK

What is the current price of PainChek?

PainChek is trading at A$0.12 per share.

What is the 52-week range for PainChek?

Over the past 52 weeks, PainChek has traded between A$0.09 and A$1.05.

How much debt does PainChek have?

As of the most recent reporting period, PainChek reported total debt of A$5.64M.

How much cash does PainChek have on hand?

PainChek reported A$5.99M in cash and cash equivalents in its most recent financial results.

What is PainChek’s dividend yield?

PainChek does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.